62 results about "Kidney dysfunction" patented technology

The present inventions relate to therapeutic compositions comprising, and methods utilizing, arachidonic acid derivatives and analogs for treatment of patients demonstrating symptoms of pathological conditions. Specifically, the inventions relate to therapeutic compositions for activating transient receptor potential vanilloid-1 channels (TRPV1). Additionally, therapeutic compositions are provided for increasing TRPV1-type responses. These pathological conditions include, but are limited to, hypertension, in particular salt induced hypertension, and cardiovascular complications, including myocardial infarction, kidney dysfunction, diabetes, and inflammation. Further, the inventions relate to drug screening methods for providing additional therapeutic compounds.

The invention provides a preparation method of a traditional Chinese medicine for treating blood stasis type reflux oesophagitis, and belongs to the technical field of preparation methods of traditional Chinese medicines. Currently, omeprazole is adopted to treat blood stasis type reflux oesophagitis, and contraindicated for use by patients allergic to the medicament, patients with serious renal insufficiency, pregnant women and infants. The preparation method is characterized by comprising the following steps of immersing the following 35 Chinese medicines in water, namely trogopterus dung, pseudo-ginseng, circium japonicum, camellia, common cephalanoplos herb, osbeckia chinensis, folium artemisiae argyi, cactus, hairyvein agrimony, rhizoma bletillae, stove, carbonized hair, rumex japonicus, marmor serpentinatum, radix boehmeriae, madder, salvia plebeian, hollyhock flower, eclipta, clove, fiveleaf akebia fruit, illicium verum, murraya jasminorage, aspongopus, sword bean, elecampane, szechwan Chinaberry fruit, mysorethorn, three-nerved spicebush root, rhizoma nardostachyos, ambergris, radix curcumae, peach kernels, safflower and liquorice; decocting with slow fire; filtering and removing slag to obtain decoction, which is the traditional Chinese medicine for treating blood stasis type reflux oesophagitis. The Chinese medicine lotion has the advantages of small toxic and side effect of prepared Chinese medicine decoction, short course of treatment and high cure rate.

The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.

The present invention provides an improved comprehensive method of assessing an individual's risk of developing CVD through analysis of multiple factors know to be associated with the development of cardiovascular disease. The factors include the classic Framingham factors of an individual's age, blood pressure, total cholesterol (TC), high-density lipoprotein (HDL) cholesterol, history of diabetes and history of cigarette smoking, in addition to factors know to be associated with increased risk of CVD including inflammation, insulin resistance, obesity, kidney dysfunction.

A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.

The invention discloses a cefotiam-hydrochloride-containing medicine preparation which is composed of an active component cefotiam hydrochloride, basic amino acid, and anhydrous sodium carbonate. The weight ratio of cefotiam hydrochloride (calculated according to cefotiam) to basic amino acid to anhydrous sodium carbonate is 1:0.4-0.6:0.05-0.15. A preparation method provided by the invention is substantially advantaged in that: (1) vacuum pumping is not needed after product sub-packaging, such that processes are reduced; (2) when the medicine is dissolved, the generation of a large amount of carbon dioxide is prevented, such that the danger for cefotiam medicine liquid to be sprayed from a bottle is avoided; (3) when the cefotiam preparation is diluted into various fluid replacements (including glucose solutions, electrolyte solutions or amino acid preparations), the amount of generated carbon dioxide is extremely low, such that clarity observation of intravenous infusion is not affected; (4) the dosage of anhydrous sodium carbonate is low, such that the possibility of alkalosis is avoided; and (5) the dosage of sodium ions is reduced, such that the preparation is suitable for patients with cardiac or renal insufficiency, edema patients, neonates, pregnant women, and the aged. Therefore, the application scope of the preparation is expended.

The invention discloses a type of polyethylene glycol erythropoietin, which is prepared from non-glycosylated rhEPO(rhngEPO) or point mutant thereof, and N-terminal amino of single and single chain PEG molecule having molecular weight greater than 20kDa or mercapto of cysteine mutational state by fixed point coupling, wherein the olyethylene glycol erythropoietin has the molecular structural formula of CH3-(CH2CH2-O)n-(CH2)r-NH-rhngEPO or CH3-(CH2CH2-O)n-X-S-rhngEPOm, wherein n is 100 to 2,200, r is 0 to 4, and X is S or C. The PEG-rhngEPO or PEG-rhEPOm molecule simultaneously has long-acting preparation characteristics such as long acting, high efficiency and low immunogenicity, and establishes foundation for preparing parent long-acting preparation for treating anemia caused by chronic renal insufficiency, tumor, anemia caused by AIDS chemotherapy, marrow brain nerve damage, and selective operation auto-transfusion.

The invention discloses a pharmaceutical composition containing sodium vitamin C and a preparation method thereof. The pharmaceutical composition contains the following components in parts by weight: 75-95 parts of sodium vitamin C, 5-10 parts of potassium chloride, pharmaceutically acceptable 0‑10 parts of accessories. The present invention overcomes the disadvantages of existing vitamin C such as high acidity and easy oxidation, and solves the clinical problem that potassium chloride produced by the combination of vitamin C and potassium chloride accelerates the oxidation of vitamin C, etc., so that the product has better stability and more definite curative effect It is suitable for patients who lack vitamin C and potassium in clinic. It can be used to treat scurvy, infectious diseases, purpura and other diseases with muscle weakness, paralysis, arrhythmia or renal dysfunction. It can also be used for malignant tumors, heart and brain. Prevention and adjuvant treatment of vascular diseases, infectious diseases, autoimmune diseases and other major difficult diseases.

The invention relates to a pure traditional Chinese medicine preparation for treating glomerular diseases. The pure traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 30 parts of membranous milkvetch root, 12 parts of amur corktree bark, 15 parts of rhubarb, 40 parts of glabrous greenbrier rhizome, 20 parts of radix salviae miltiorrhizae, 15 parts of oriental waterplantain rhizome, 20 parts of epimedium herb, 15 parts of lalang grass rhizome and 30 parts of motherwort herb, and prepared by decoction, filtration, concentration of filtrate and drying. The pure traditional Chinese medicine preparation has significant efficacy for kidney diseases comprising acute and chronic glomerulonephritis, nephrotic syndrome, hypertensive nephropathy, diabetic nephropathy and early renal insufficiency caused by various reasons; furthermore, the raw materials are easily available, the production process is simple, the toxicity and side effects are small, and the administration is convenient, thereby providing the effective pure traditional Chinese medicine preparation for treating the kidney diseases.

The invention discloses composite Shenque moxibustion. The composite Shenque moxibustion is characterized by comprising a medical hot-melt pressure-sensitive adhesive located at the bottom, air permeable infiltration pores are distributed in the medical hot-melt pressure-sensitive adhesive, moxa floss composite medicine sticks to the middle of the medical hot-melt pressure-sensitive adhesive, and the outer layer of the moxa floss composite medicine is coated with tourmaline materials; the moxa floss composite medicine is prepared from, by weight, 80-95 parts of moxa floss, 3-5 parts of dried ginger, 1-5 parts of prepared common monkshood daughter roots, 0.5-1 part of halite and 2-5 parts of peach seeds, and the dried ginger, the prepared common monkshood daughter roots, the halite and the peach seeds which are in a powder form are mixed with the moxa floss. According to the composite Shenque moxibustion, positive stimulation to human bodies is achieved, the physique is strengthened greatly, the composite Shenque moxibustion can be used for sick bodies and healthy bodies, the function of promoting development of weak children is specially achieved, a good abdominal Qi transformation function is achieved, and the good curative effects on frequent micturition and urine waiting which are caused by senile prostatitis, hyperplasia and kidney dysfunction in Qi holding are achieved.

The present invention discloses one kind of nephropathy treating medicine composition and its preparation process. The Chinese medicine composition is prepared with Nippon yam rhizome, bupleurum root, angelica, astragalus root and leech. It is used in treating mesenchymal disease of glomerulum and renaltubule, chronic glomerulonephritis, renal disease, nephritic syndrome, etc. It has determined curative effect.

The invention relates to a traditional Chinese medicinal composition for curing chronic renal insufficiency. The traditional Chinese medicinal composition comprises the following traditional Chinese medicinal raw materials, by weight, 10-40 parts of Radix Astragali, 10-30 parts of cistanche, 5-20 parts of tree peony bark, 5-25 parts of rhizoma alismatis, 10-40 parts of Gorgon fruit, 5-20 parts of cyathula root, 5-25 parts of morinda officinalis, 10-40 parts of Curculigo orchioides, 10-30 parts of Plantain seed, 10-40 parts of raw rehmannia root, 5-20 parts of radix paeoniae rubrathe, 10-30 parts of fleece-flower root, 10-40 parts of Chinese yam, 10-30 parts of Indian bread, 10-30 parts of white hyacinth bean, 10-40 parts of lotus seed, 5-20 parts of sophora bud, 5-25 parts of rhizoma Gastrodiae, 10-30 parts of serissa serissoide, 5-25 parts of semen persicae, 5-20 parts of semen astragali complanati, 10-30 parts of motherwort and 5-15 parts of licorice. The traditional Chinese medicinal composition has effects of nourishing liver, invigorating spleen, reinforcing kidney to strengthen yang, tonifying the kidney to control nocturnal emission with astringent drugs, invigorate blood circulation and nourishing blood, detoxifying and eliminating dampness, and has a remarkable curative effect of curing chronic renal insufficiency. The effects of the traditional Chinese medicinal composition are reliable.

The invention provides a composition for improving kidney dysfunction and belongs to the technical field of ginseng deep-processing. The composition comprises, by weight, 2-6 parts of ginsenoside Rg2,1-5 parts of ginsenoside Rg5 and 1-3 parts of ginsenoside Rk1. The composition participates in slowing down the progress of chronic kidney interstitial fibrosis by inhibiting HK-2 phenotypic differentiation so as to improve chronic kidney dysfunction. It is verified that the composition can remarkably improve kidney functions of patients at 2-3 stages of chronic kidney dysfunction CKD.

It is intended to provide a highly safe, orally administrable preventive and/or therapeutic agent for thrombosis and/or embolism that can be applied to a thrombosis and/or embolism patient with severe renal impairment. The present inventors have found that even for a thrombosis and/or embolism patient with severe renal impairment, use of edoxaban at a dose of 15 mg once a day can effectively prevent thrombosis and/or embolism while avoiding the risk of bleeding. The present inventors have also found that even for a thrombosis and/or embolism patient with severe renal impairment, edoxaban at a dose of 15 mg once a day can effectively prevent thrombosis and/or embolism with safety over a long period.

(a) diagnosing or monitoring kidney function in a subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse event in a diseased subject, wherein said adverse event is selected from the group comprising worsening of kidney function including kidney failure, loss of kidney function and end-stage kidney disease or death due to kidney dysfunction including kidney failure, loss of kidney function and end-stage kidney disease or (d) predicting or monitoring the success of a therapy or intervention:

• • determining the level of Pro-Enkephalin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and
  • correlating said level of Pro-Enkephalin or fragments thereof with kidney function in a subject.